Medical/Pharmaceuticals

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022. * The Company makes remarkable progress on environmental goals, achieving its water consumption intensity-reduction target in 2022, well a...

2023-04-28 14:43 2956

Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio

- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development expertis...

2023-04-28 08:58 2137

Ubie signs a broad collaboration agreement with Takeda Pharmaceuticals to promote digital transformation

- Aims to guide patients with rare and gastrointestinal diseases to appropriate medical care 〜Ubie will build on its achievements in the early detection of HAE and expand its collaboration with Takeda Pharmaceuticals to benefit patients in broader disease areas〜 NEW YORK, April 27, 2023 /PRNews...

2023-04-27 23:00 1881

Healint announces a collaboration with Saitama Medical University Hospital, Japan, to verify AI diagnosis of Migraine

PALO ALTO, Calif., April 27, 2023 /PRNewswire/ -- Saitama Medical University Hospital and Healint launched one of the world's first clinical studies titled "Verification of Headache AI diagnosis by using Electronic Headache Diary in Telemedicine". About 20 renowned headache specialists partici...

2023-04-27 21:15 2051

Yuyu Pharma, Dry Eye Pipeline Mechanism of Action and Pre-clinical Results Published

SEOUL, South Korea, April 27, 2023 /PRNewswire/ -- At ARVO 2023, Yuyu Pharma unveiled the results of its mechanism of action and head-to- head studies for its dry eye treatment peptide (project name: YP-P10). ARVO is the world's largest ophthalmic society and held its annual meeting inNew Orleans...

2023-04-27 21:00 2070

ASCO 2023 | Ascentage Pharma to Present Results from 4 Studies Highlighting Extended Therapeutic Potential of Lead Drug Candidates

SUZHOU, China, and ROCKVILLE, MD, April 27, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clinical studies of the c...

2023-04-27 17:44 1813

Dizal's Rapidly Evolving Oncology Pipeline to Make Waves at 2023 ASCO Meeting

Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presentations SHANGHAI, April 26, 2023 /PRNewswire/ -- Dizal today announced that multiple clinical data of its two leading assets – sunvozertinib and golidocitinib have been selected for presentations...

2023-04-27 07:20 2070

Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative

SHANGHAI, April 26, 2023 /PRNewswire/ --  On April 25, 2023, World Health Organization (WHO) gave as the theme for World Malaria Day 2023 Time to deliver zero malaria: invest, innovate, implement. Within this theme, WHO will mainly focus on the third "i" – implement – and notably the critical imp...

2023-04-26 22:32 3722

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...

2023-04-26 22:15 3070

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of ul...

2023-04-26 21:16 2896

J INTS BIO, AACR 2023 - Presentation of preclinical study results of 'JIN-A04', an oral target therapy for HER2 exon insertion mutation NSCLC

SEOUL, South Korea, April 25, 2023 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered TKI 'JIN-A04' targeting NSCLC with HER2 exon 20 insertion mutation at the annual meeting of the American Association of Cancer Research 2023, which was held inOrlando,...

2023-04-26 09:53 1662

BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States

* The Official State visit by the President of the Republic of Korea marks the 70th anniversary of the U.S.-ROK alliance, which is advancing peace, stability, and prosperity for the two countries, for theAsia-Pacific region, and globally * President Yoon Suk Yeol and First Lady Kim Keon Hee o...

2023-04-25 20:00 1506

Mediso launches next generation MRI spectrometer spinScan®

BUDAPEST, Hungary, April 25, 2023 /PRNewswire/ -- Mediso released their next generation MRI spectrometer spinScan® the successor to the previously used console in the nanoScan® MRI product line. The new spectrometer was optimized for MRI applications delivering an ultra-low-...

2023-04-25 16:00 1920

Nippon Express (UK) Receives IATA CEIV Pharma Certification for Its Facility in Heathrow Airport Suburb

TOKYO, April 25, 2023 /PRNewswire/ -- Nippon Express (UK) Ltd. (hereinafter "NXUK"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been awarded IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association (I...

2023-04-25 15:00 1945

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

* Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute * Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to T...

2023-04-25 13:46 1819

Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company's Quality Management System

SUZHOU, China and ROCKVILLE, Md., April 24, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it recently received a zero-deficiency repor...

2023-04-25 08:42 1848

EDAN Presented a Regional Development Blueprint for the Delegation from the Colombian Consulate

SHENZHEN, China, April 24, 2023 /PRNewswire/ -- The Consul General of Colombia inGuangzhou, Hernan Vargas Martin, led a delegation to visit the headquarter of Edan Instruments, Inc. (300206.SZ) in Shenzhen , and exchanged development strategies and actions of Lati...

2023-04-24 23:12 2789

A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology

SHANGHAI, April 24, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. ("OBiO" or "the Company"), a leading gene and cell therapy CDMO inChina, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in theChina (Shang...

2023-04-24 22:36 2998

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational tri...

2023-04-24 21:00 1929

AITRICS to Participate in HIMSS USA 2023

* Introducing an AI Solution for predicting patient deterioration, 'VitalCare' * Second HIMSS USA Participation...Finding potential customers and establishing a foothold in the US market SEOUL, South Korea, April 24, 2023 /PRNewswire/ -- AITRICS (CEO Kwang joon Kim, Jin-gyu Yoo), a company spe...

2023-04-24 21:00 1773
1 ... 81828384858687 ... 214

Week's Top Stories